Survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective cohort study.
Cervical cancer
Ethiopia
Survival status
Tikur Anbesa Specialized Hospital
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
16 Dec 2019
16 Dec 2019
Historique:
received:
27
08
2019
accepted:
09
12
2019
entrez:
18
12
2019
pubmed:
18
12
2019
medline:
7
5
2020
Statut:
epublish
Résumé
Cervical cancer is a cancer of uterine cervix caused mostly by sexually-acquired infection called Human papillomavirus (HPV. In developing region of the globe, fewer than 50% of women with cervical malignancy survive more than 5 years. Therefore, the objective of this study was to assess survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital (TASH), Ethiopia. Facility based retrospective cohort study was conducted from March to April 2019 at Tikur Anbesa Specialized Hospital oncology center. Data was collected from patient's chart using pre-tested and structured checklist prepared in English and analyzed using STATA14.2. Cox regression model was used to identify Variables that affected survival. The overall survival rate was 38.62% at 5 years. There were a significance differences in survival experience between categories of stage of cervical cancer, age of patients, comorbidity, substance use, base line anemia and treatment modalities. Being stage IV [AHR = 11.76; 95% CI (4.02-34.4)],being advanced age [AHR = 5.99; 95% CI (2.1-17.08)], being comorbid [AHR = 1.58; 95%CI(1.14-2.19)], using substance [AHR = 1.56;95% CI(1.09-2.22)] and being anemic [AHR = 1.6;95% CI(1.11-2.36)] increased the risk of death. The overall survival rate was lower than high- and middle-income countries and Significant factors of death after diagnosis of cervical cancer were; advanced FIGO stage, base line anemia, comorbidity, substance use, advanced age and treatment modality. Authors recommend that it is better to expand cervical cancer early screening programs and treatment facilities, strengthen awareness in collaboration with public medias about cervical cancer prevention, screening and treatment options.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer is a cancer of uterine cervix caused mostly by sexually-acquired infection called Human papillomavirus (HPV. In developing region of the globe, fewer than 50% of women with cervical malignancy survive more than 5 years. Therefore, the objective of this study was to assess survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital (TASH), Ethiopia.
METHODS
METHODS
Facility based retrospective cohort study was conducted from March to April 2019 at Tikur Anbesa Specialized Hospital oncology center. Data was collected from patient's chart using pre-tested and structured checklist prepared in English and analyzed using STATA14.2. Cox regression model was used to identify Variables that affected survival.
RESULT
RESULTS
The overall survival rate was 38.62% at 5 years. There were a significance differences in survival experience between categories of stage of cervical cancer, age of patients, comorbidity, substance use, base line anemia and treatment modalities. Being stage IV [AHR = 11.76; 95% CI (4.02-34.4)],being advanced age [AHR = 5.99; 95% CI (2.1-17.08)], being comorbid [AHR = 1.58; 95%CI(1.14-2.19)], using substance [AHR = 1.56;95% CI(1.09-2.22)] and being anemic [AHR = 1.6;95% CI(1.11-2.36)] increased the risk of death.
CONCLUSION
CONCLUSIONS
The overall survival rate was lower than high- and middle-income countries and Significant factors of death after diagnosis of cervical cancer were; advanced FIGO stage, base line anemia, comorbidity, substance use, advanced age and treatment modality. Authors recommend that it is better to expand cervical cancer early screening programs and treatment facilities, strengthen awareness in collaboration with public medias about cervical cancer prevention, screening and treatment options.
Identifiants
pubmed: 31842805
doi: 10.1186/s12885-019-6447-x
pii: 10.1186/s12885-019-6447-x
pmc: PMC6916089
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1221Références
Int Health. 2018 Mar 1;10(2):92-99
pubmed: 29432549
PLoS One. 2017 Nov 16;12(11):e0187579
pubmed: 29145414
Oncologist. 2018 Sep;23(9):1024-1032
pubmed: 29567823
Infect Agent Cancer. 2016 Mar 24;11:15
pubmed: 27014366
J Clin Oncol. 2016 Nov 1;34(31):3749-3757
pubmed: 27573661
Asian Pac J Cancer Prev. ;17(11):4837-4844
pubmed: 28030908
J Cancer. 2018 Feb 12;9(5):851-860
pubmed: 29581763
Br J Cancer. 2013 Oct 29;109(9):2489-95
pubmed: 24030072
Cytopathology. 1992;3(3):139-48
pubmed: 1511118
Asian Pac J Cancer Prev. 2015;16(7):3067-72
pubmed: 25854407
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S205-S210
pubmed: 29644674
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1434-8
pubmed: 22806169
Lancet Oncol. 2013 Apr;14(4):289-90
pubmed: 23561741
Infect Agent Cancer. 2017 Nov 29;12:61
pubmed: 29213299
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
J Cancer Res Ther. 2018 Jul-Sep;14(5):1089-1093
pubmed: 30197354
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Asian Pac J Cancer Prev. 2002;3(3):207-214
pubmed: 12718577
PLoS One. 2018 May 8;13(5):e0196764
pubmed: 29738533
PLoS One. 2013 Oct 30;8(10):e78411
pubmed: 24205226